Accueil>>Signaling Pathways>> Immunology/Inflammation>> NO Synthase>>Asymmetric dimethylarginine

Asymmetric dimethylarginine (Synonyms: ADMA, Asymmetric dimethylarginine)

Catalog No.GC32457

La diméthylarginine asymétrique est un inhibiteur endogène de l'oxyde nitrique synthase (NOS) et fonctionne comme un marqueur de la dysfonction endothéliale dans un certain nombre d'états pathologiques.

Products are for research use only. Not for human use. We do not sell to patients.

Asymmetric dimethylarginine Chemical Structure

Cas No.: 30315-93-6

Taille Prix Stock Qté
10mM (in 1mL Water)
61,00 $US
En stock
5mg
56,00 $US
En stock
25mg
175,00 $US
En stock

Tel:(909) 407-4943 Email: sales@glpbio.com

Avis des clients

Based on customer reviews.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents Related Products

Asymmetric dimethylarginine is an endogenous inhibitor of nitric oxide synthase (NOS), and functions as a marker of endothelial dysfunction in a number of pathological states.

Asymmetric dimethylarginine is an endogenous inhibitor of nitric oxide synthase (NOS), and functions as a marker of endothelial dysfunction in a number of pathological states. Asymmetric dimethylarginine (ADMA) is elevated in HIV-1 infection[1].

[1]. Hudson CL, et al. The cardiovascular risk marker asymmetric dimethylarginine is elevated in asymptomatic, untreated HIV-1 infection and correlates with markers of immune activation and disease progression. Ann Clin Biochem. 2014 Sep;51(Pt 5):568-75.

Avis

Review for Asymmetric dimethylarginine

Average Rating: 5 ★★★★★ (Based on Reviews and 19 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for Asymmetric dimethylarginine

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.